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Previous work has shown that the 68-kDa immediate-early protein of herpes simplex virus type 1 (HSV-1), also known as
ICP22, is involved in the control of viral gene expression, although the precise mechanism remains to be elucidated. In
order to study the function(s) of this protein, we constructed expression vectors containing the coding sequence of the
ICP22 gene placed under the control of the SV40 or HCMV promoter. After cell transfection, ICP22 synthesis was studied
by immunoblotting, using a specific antiserum. In transient expression experiments in COS cells in which the ICP22 vector
was under the control of the SV40 promoter, we found that ICP22 was able to inhibit chloramphenicol acetyltransferase
(CAT) expression under the control of either the a22 (IE4) promoter or other immediate-early promoters, such as a4 (IE3),
a0 (IE1), and a27 (IE2). CAT expression under the control of the a4 (IE3) promoter was inhibited in these cells by expression
of ICP22 under the control of the HCMV promoter; it was also inhibited in RAT-1 cells by ICP22 expressed under the control
of the SV40 or HCMV promoter. In contrast, CAT expression directed by the SV40 or HCMV promoters was only weakly
or not inhibited by the ICP22 vectors. We also constructed an expression vector for UL13, a gene whose product is implicated
in the phosphorylation of ICP22. Although CAT expression under the control of the a4 (IE3) promoter was also negatively
regulated by the UL13 gene product, the effects of the ICP22 (directed by the SV40 or HCMV promoter) and UL13 vectors
were not synergistic; furthermore, at a particular molar ratio of the two vectors, inhibition of CAT activity was partially
reversed. The results in the present work suggest that ICP22 can negatively regulate the expression of immediate-early
viral genes and that its phosphorylation by UL13 protein kinase might be involved in the modulation of its function. q 1996
Academic Press, Inc.
INTRODUCTION a major role in reactivation from latency (Cai et al., 1993)
(for review, see Roizman and Sears, 1991).
In cells lytically infected with herpes simplex virus The situation with regard to ICP22 is not entirely clear.
type-1 (HSV1), the first genes to be transcribed are desig- In transient transfection assays, ICP22, both alone and
nated a, or immediate-early (IE), genes and encode five in combination with other immediate-early proteins,
proteins, designated ICP0, 4, 22, 27, and 47. Genetic shows no ability to transactivate HSV1 promoters (O’Hare
studies have shown that the genes coding for ICP4 and and Hayward, 1985). However, in certain cell lines in-
27 are essential for viral growth and exert a regulatory fected with a virus containing a deletion in the ICP22
role. ICP4 is the major protein involved in transcription gene, late gene expression is reduced, suggesting a cell-
regulation in HSV-1 (Mackem and Roizman, 1982; Deluca type-dependent role for this protein in the activation of
et al., 1985; Gelman and Silverstein, 1987); it is necessary this class of genes (Sears et al., 1985). More recently,
during infection for the activation of the b, or early (E), ICP22 has been implicated in the modification of the host
and g, or late (L), genes (Watson and Clements, 1980) RNA polymerase II (Rice et al., 1995). The ICP22 gene
and also represses the expression of all the a genes has some interesting characteristics. Its regulatory se-
(O’Hare and Hayward, 1985). ICP27 appears to mediate quences, shared with the ICP47 gene, overlap those of
the transition from the b to the g phase of viral infection the ICP4 gene and of the viral origin of replication, OriS.
and also transactivates g genes and represses a and b The gene consists of two exons and one intron, the entire
genes, in combination with ICP4 and ICP0 (Sekulovich coding sequence being located in exon 2 in the unique
et al., 1988). Other IE genes are not essential for viral short sequence of the HSV-1 genome. The protein is
growth in all cell types, but have been implicated as guanylated, adenylated, and phosphorylated, and at least
playing a role in gene expression. In particular, ICP0 part of these posttranslational modifications involve the
transactivates a, b, and g genes and is thought to play viral protein kinases encoded by UL13 and US3 and ca-
sein kinase II (Purves and Roizman, 1992; Blaho et al.,
1993; Purves et al., 1993; Mitchell et al., 1994). To study1 Present address: UMR 49, Ecole Normale Supe´rieure, Lyon, France.
how ICP22 might modulate viral gene expression during2 To whom correspondence and reprint requests should be ad-
dressed. infection, we constructed two expression vectors in
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which the coding sequences of ICP22 and UL13 were promoter, was obtained from Dr. G. Tiraby (Baron et al.,
1992).placed under the control of the SV40 and/or HCMV pro-
moters. Using transient expression assays, we then ana-
Transfection assayslyzed the effects of ICP22 vectors on IE viral gene expres-
sion in the presence and absence of UL13. The results
Cells (0.6 1 106) were seeded in cell culture flasks
indicate that ICP22 can repress the expression of CAT
and then transfected 8 hr later, using the calcium method
directed by IE promoters, including the a22 promoter,
(Graham and Van Der Eb, 1973) or lipofectamine (Gibco-
and that this inhibition can be partially reversed by the
BRL), with 15 mg of herring sperm (HS) DNA or a mixture
UL13 vector at a particular molar ratio of the two vectors.
of plasmid DNAs (15 mg of DNA) plus HS.
MATERIALS AND METHODS Immunoblotting
Cells, virus, and viral DNA Cells were transfected with plasmid DNA, as pre-
viously described. Twenty and 72 hr after transfection,COS and Vero cell lines were obtained from the Ameri-
they were washed with PBS and then sonicated, and thecan Type Culture Collection and Rat-1 was from Wein-
debris was removed by centrifugation. The proteins inberg’s laboratory (MIT, Cambridge, MA). HSV1(F) (Heine
the supernatant were separated by electrophoresis onet al., 1974) was provided by Dr. B. Roizman (University
10% SDS–polyacrylamide gels, transferred electropho-of Chicago). Viral DNA was purified from the cytoplasm
retically to nitrocellulose membranes, then washed withof infected Vero cells by banding in Nal equilibrium gradi-
water. To prevent nonspecific antibody binding, the mem-ents (Walboomers and Ter Scheggett, 1976).
brane was treated with 5% fat-free milk in PBS, before
being incubated for 1 hr with a specific rabbit anti-ICP22Construction of plasmids
antiserum provided by B. Roizman (Ackerman et al.,
1985). The blots were washed three times with PBS con-The fragment BamHI– BstEII, containing the a22 gene
taining 0.2% Triton X-100 and then incubated for 1 hr with(pBN/1) (Garcin et al., 1990), was subcloned into pBlue-
goat anti-rabbit immunoglobulin antibodies conjugatedscript (SK, Stratagene) between the EcoRI and ClaI re-
to alkaline phosphatase. After three washes as above,striction sites. The 5* noncoding sequence of this gene,
the color reaction was developed using nitroblue tetrazo-including the first exon and part of the intron, was deleted
lium (Sigma) and 5-bromo-4-chloro-3-indolyl phosphateby exonuclease III and mung bean nuclease digestion.
(Sigma) as substrates (Garcin et al., 1990).Various deleted plasmids were isolated and sequenced
and one, designated p22, containing eight additional nu-
CAT and LacZ assayscleotides outside the open reading frame, was selected
for further cloning. The fragment BamHI– SalI, containing
Seventy-two or 96 hr after transfection, the cell lysates
the a22 gene, was filled in with Klenow enzyme and
were analyzed for CAT activity, as described by Gorman
cloned at the SmaI site of plasmid pcEXV3 (Miller and
et al. (1982), using 0.2 mCi of [14C]chloramphenicol (60
Germain, 1986) (referred to as pEX), downstream of the
mCi/mmol, NEN). All quantitative comparisons were
SV40 promoter; the product was designated pEX22.
made by measuring the mono- and diacetylated deriva-
pCMV/CAT (Foecking and Hofstetter, 1986) was digested
tives of chloramphenicol on the linear part of the prod-
with HindIII and EcoRI to delete the CAT cDNA. Following
uct–enzyme concentration graphs. LacZ activity was de-
Klenow treatment, the filled ends were either directly
termined colorimetrically by the absorbance at 570 nm
ligated, producing pCMV, or ligated to the blunt-ended
using chlorophenol red–b-D-galactopyranoside (CPRG)
BamHI–SalI fragment described above, producing
as substrate (Eustice et al., 1991).
pCMV22. To construct the UL13 vector, a BglII fragment
from HSV1 (F) DNA (Perry and McGeoch, 1988) was In vitro transcription and translation and
cloned into the BamHI site of SK plasmid. A KpnI frag- immunoprecipitation of the translation product
ment was then deleted, producing pUL13, and a KpnI –
XbaI fragment was cloned into the SmaI site of pEX, In vitro transcription reactions were performed in a
volume of 50 ml containing 0.5 mg of pUL13 or p22 andplacing UL13 under the control of the SV40 promoter.
Finally, the region between the BalI and SpeI sites was using T3 or T7 polymerase, respectively, followed by in
vitro translation in the presence of 40 mCi of [35S]-deleted, producing pEXUL13.
The plasmids pIGA72, 65, 106, and 98, containing the methionine (1000 Ci/mmol, NEN). RNA and protein syn-
theses were carried out using TNT-coupled reticulocyteCAT gene under the respective control of the a4, 0, 22/
47, and 27 regulatory-promoter sequences were ob- lysate systems (Promega), following the manufacturer’s
instructions.tained from S. Silverstein (Gelman and Silverstein, 1987).
pSV2CAT (Gorman et al., 1982) was used as a control. Immunoprecipitation of in vitro-translated UL13 protein
was achieved using Staphylococcus aureus (Pansorbin,pUT535, containing LacZ under the control of the HCMV
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Calbiochem), previously activated in RIPA buffer (10%
SDS, 0.1% Tween, 1% DOC, 0.15 M NaCl, 10 mM Tris,
pH 7.4, 1 mM EDTA, and 0.25 mM PMSF), diluted in
the same buffer and immunoprecipitated with anti-UL13
polyclonal rabbit antiserum provided by A. Davidson
(Cunningham et al., 1992), as described by the authors.
Protein kinase assay
Proteins were extracted from the nuclei of mock-in-
fected or HSV-1-infected cells and from pEX- or pEXUL13-
transfected cells, using salt washes, followed by ammo-
nium sulfate precipitation (Piette et al., 1985). Nuclear
extracts, or aliquots of previously washed immunoprecip-
itates (three times with PBS), were suspended in 50 ml
of protein kinase buffer (20 mM Tris–HCl, pH 8, 1.5 M
NaCl, 50 mM MgCl2 , 1 mM dithiothreitol, 0.1% Nonidet FIG. 1. Immunoblot of ICP22 extracted from infected and transfected
cells. COS cells were infected with 20 PFU/cell of HSV1(F) or trans-P40); 1.5 M casein was added to some samples (Cun-
fected with 15 mg of pCMV22, pBN/1, herring sperm DNA (C), or pEX22ningham, et al., 1992). The assay was initiated by the
DNA, and the proteins were separated by electrophoresis, transferredaddition of 1 mCi of [g-32P]ATP (3000 Ci/mmol; NEN). to nitrocellulose membranes, and treated with anti-ICP22 antiserum.
After incubation of the reaction mixture at 377C for 30 HSV1-infected Vero and COS cells were used as controls. On the right,
min, the nuclear extracts or immunoprecipitates were the position of the main form of ICP22 and molecular weight markers
are shown.washed three times with PBS buffer, boiled for 5 min in
denaturing buffer, and analyzed by 10% SDS–polyacryl-
amide gels. To quantify the radioactivity in nuclear ex-
The ICP22 vector inhibits CAT expression fromtracts, aliquots were precipitated with 10% TCA in the
regulatory regionspresence of cold ATP.
We then analyzed the regulation in COS cells of the
RESULTS HSV-1 a4 promoter by the pEX22 and pCMV22 expres-
sion vectors, using a plasmid containing a4 regulatoryAnalysis of ICP22-encoding plasmids
sequences upstream of the reporter CAT gene (pIGA72).
Figure 2A shows the percentage of mono- and diace-COS cells were either infected with HSV1(F) or trans-
fected with pCMV22, pEX22, or pBN/1, corresponding, tylated chloramphenicol produced versus the concentra-
tion of pEX22 or pCMV22 used; dose-dependent inhibi-respectively, to the ICP22 coding sequence under the
control of the HCMV, SV40, or natural promoter. Twenty- tion of CAT expression can be seen. Using 10 and 5 mg,
respectively, of the vectors pEX and pCMV (lacking thefour hours later, the cells were lysed and the soluble
protein extracts analyzed by Western blots, using a spe- a22 coding sequence), there was essentially no inhibi-
tion of CAT activity (data not shown).cific anti-ICP22 antiserum (Fig. 1).
Following transfection, the expression vectors con- To confirm that the inhibition of IE gene expression
was specific, three further experiments were carried out.taining the HCMV or SV40 promoters produced detect-
able amounts of ICP22. Using the specific antibody, sev- First, COS cells were transfected with pIGA72 plus a
series of mixtures of pEX / pEX22 (2 mg total) or pCMVeral immunoreactive bands with apparent molecular
weights between 70 and 90 kDa were seen in both Vero / pCMV22 (5 mg total), a protocol designed to add in-
creasing amounts of the a22 coding region while keep-and COS cells; more ICP22 was produced by the SV40
promoter-containing vector than by that containing the ing the total amount of regulatory region constant to en-
sure that any effects seen were due to ICP22 ORF; aHCMV promoter. Several higher molecular weights
bands were also seen, although at a lower intensity than dose-dependent inhibition of CAT expression similar to
that shown in Fig. 2A was observed (Fig. 2B). No differ-in infected cells. In pCMV22-transfected COS cells, a
weak 70-kDa immunoreactive band was seen. Under the ence between cells transfected with either pIGA72 alone
or pIGA72 in the presence of pEX or pCMV was detected;control of its natural promoter (pBN1), no ICP22 synthesis
was detectable, although the plasmid contains regulatory the percentages of acetylated CAT, before (Fig. 2B) nor-
malization, were 91.7 { 0.2 and 86.7 { 4.3%, with orsequences located both upstream (Roizman and Sears,
1991) and downstream (Greco et al., 1994) of the tran- without pEX, and 93 { 0.5 and 89.2 { 2.1%, with or
without pCMV, respectively, suggesting that the ICP22scription initiation site. A faint nonspecific high molecular
weight band was seen in all samples from COS-trans- vectors lacking the coding sequence have no effect on
the a4 promoter. Second, the ability of increasedfected cells.
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FIG. 2. Inhibition of CAT expression by ICP22 under the control of immediate-early or heterologous promoters. COS cells were cotransfected:
(A) with 5 mg of pIGA72 (containing a4 promoter) and increased concentrations of pEX22 or pCMV22 as effectors; (B) with 5 mg of pIGA72, pCMVCAT,
or pSV2CAT and 2 mg of the mixtures pEX/pEX22 or pCMV/pCMV22 as effectors. The circles represent the effect of pEX22 or pEX/pEX22 on
PIGA72, the squares represent that of pCMV22 or pCMV/pCMV22 on pIGA72, the diamonds represent that of pEX/pEX22 on pCMVCAT, and the
triangles represent that of pCMV/pCMV22 on pSV2CAT. The values shown are the percentage of acetylated chloramphenicol versus the concentra-
tion of the effector, ICP22 (pEX22 or pCMV22). Standard deviations are reported for 4 mg of expression vectors. The autoradiograms of the
chromatograms for A are shown at the bottom of the figure.
amounts of both plasmids (pEX22 and pCMV22) to inhibit 22/47, and 27, were tested with pEX22. Dose-dependent
inhibition was again seen, being more efficient with theCAT expression driven by heterologous promoters in
COS cells was evaluated under the same conditions (Fig. a0 promoter (pIGA65) than with either the a22/47
(pIGA106) or a27 (pIGA98) promoters (Fig. 3A).2B). With 4 mg of pEX22 on pCMVCAT and with 4 mg of
pCMV22 on pSV2CAT, the results of three such experi- Finally, the ability of ICP22 to inhibit CAT expression
was tested using pIGA72 in the Rat-1 cell line, whichments shown in Fig. 2B, gave respective CAT activities
of 93 { 2.5 and 89 { 5%, suggesting that the ICP22 cannot complement a lack of ICP22 (Sears et al., 1985).
The results, shown in Fig. 3B, demonstrate that, althoughvector could either not inhibit or only weakly inhibit heter-
ologous promoters. Third, the same specificity was seen higher concentrations of plasmid were required, both
pEX22 and pCMV22 were able to inhibit CAT expressionfor the HSV1 promoter in COS cells cotransfected with
a mixture of CAT plasmid and LacZ plasmid under the from pIGA72 in these cells. Thus, the ICP22 vector can
inhibit all IE promoters, including itself, and is effectiverespective control of the a4 promoter-regulatory region
(pIGA72) and the HCMV promoter-regulatory region in two different cell types.
(pUT535). LacZ expression, determined colorimetrically,
was not affected by increasing concentrations of pXE22, A plasmid expressing the UL13 gene product inhibits
the absorbance at 570 nm (using CPRG as substrate) CAT expression from pIGA72 and can partly reverse
varying between 0.70 and 0.79 for amounts of pEX22 the inhibitory effect of ICP22
ranging from 0 to 2 mg. Thus, ICP22 is able to specifically
block the a4 promoter. It has previously been noted that the protein kinase
encoded by the UL13 gene of HSV1 can influence theThree other IE reporter plasmids, pIGA65, 106, and 98,
which carry, respectively, regulatory sequences for a0, posttranslational processing associated with phosphory-
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FIG. 3. Inhibition of CAT expression under the control of immediate-early promoters by ICP22. (A) COS cells were cotransfected with 5 mg of
pIGA98 (squares), 65 (diamonds), or 106 (circles), corresponding to the a27, 0, and 22 promoters, respectively, and with 2 mg of the mixture
pEX/pEX22. (B) Rat-1 cells were cotransfected with 5 mg of pIGA72 and 2 mg of the mixture pEX/pEX22 (circles) or pCMV/pCMV22 (squares).
The values shown are the percentages of acetylated chloramphenicol versus the concentrations of the effector, ICP22 (pEX22 or pCMV22).
lation of ICP22, thereby altering its function (Purves and Finally, the protein kinase activity of pEXUL13 was
tested by its autophosphorylation by 32P-labeled g-ATPRoizman, 1992). To study whether the UL13 gene product
might exert an effect on the inhibitory effect of ICP22 on using nuclear extracts of COS cells transfected with 10
mg of either pEX or pEXUL13; the TCA precipitable radio-CAT expression, we constructed two vectors expressing
UL13 under the control of either the T3 promoter (pUL13) activity was 3638 cpm/mg of protein for pEXUL13, 534
or the SV40 promoter (pEXUL13).
The pUL13 and p22 vectors, containing the coding
sequences for UL13 and ICP22 directed by the T3 and
T7 promoter, respectively, were transcribed in vitro and
translated in the presence of [35S]methionine. The results
(Fig. 4, left) show that, in the case of ICP22, three bands
were seen, corresponding to three different open reading
frames, the largest with the same molecular weight as
ICP22 (lane 1), while, for UL13, three bands were also
seen (lane 2), but, after immunoprecipitation with UL13-
specific antiserum, only one band with a molecular
weight of 57 kDa (identical to that of UL13) was detected
(lane 3).
Aliquots of unlabeled UL13 immunoprecipitates were
incubated with 32P-labeled g-ATP in protein kinase buffer
in the presence of casein, a known heterologous sub-
strate for UL13 (Cunningham et al., 1992) or of in vitro-
translated ICP22 (Fig. 4, right). Highly efficient phosphor-
ylation of casein (lane 2) and weak autophosphorylation
of UL13 were seen (lane 3). Various labeled bands, with
FIG. 4. Identification and enzymatic activity of the UL13 protein. (Left)molecular weights higher than the 68 kDa marker, corre-
Autoradiograph of in vitro translation in reticulocyte lysates after in vitrosponding to the range of molecular weights noted in
transcription of p22 (left side) or UL13, before (0IP) or after (/IP),infected cells (Fig. 1), were seen with ICP22 in the pres-
immunoprecipitation with specific anti-UL13 antibodies. (Right) In vitro
ence of UL13 (lane 4). No casein phosphorylation oc- phosphorylation of casein alone and either casein, in vitro-translated
curred in the absence of UL13 (lane 1); thus UL13 pos- buffer alone or in vitro-translated ICP22 with immunoprecipitated UL13
protein. Molecular weight markers are shown on the right.sesses functional protein kinase activity.
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FIG. 5. Effect of UL13 on the inhibitory effect of ICP22 on immediate-early promoters. COS cells were transfected (left) using the calcium method
with 5 mg of pIGA72 and various amounts of pEX (lanes 5), pEXUL13 (lanes 2–4), or pEX22 (lane 6) or various proportions of the mixtures
pEX22/pEXUL13 (lanes 7–9) or pEX/pEXUL13 (lanes 10 and 11); (right) using lipofectamine with 1 mg of pIGA72 and various amounts of pCMV22
alone (lanes 13–15) or 1 mg of pCMV22 in combination with variable amounts of pEXUL13 (lanes 16 and 17). The upper part of the figure shows
the autoradiograms of chromatograms, while the percentages of acetylated chloramphenicol and pIGA72 inhibition are given below the figure.
cpm/mg for pEX-transfected cells, 65,441 cpm/mg for ly- (columns 12–15). The 81% inhibition produced by 1 mg
of pCMV22 fell to 58% on addition of 0.5 mg of pEXUL13sates of infected cells (24 hr after infection with 20 PFU/
cell of HSV1), and 585 cpm/mg for lysates of uninfected (column 16). As in the previous experiment, increasing
the amount of pEXUL13 resulted in further inhibition ofcells. This high level of phosphorylation is relevant in
terms of the stimulation of several protein kinases follow- pIGA72 (column 17). These observations suggest either
that, at a certain specific ICP22/UL13 ratio, the UL13ing viral infection (Lemaster and Roizman, 1980).
Since our UL13 vectors clearly expressed a functional vector can partially reverse the inhibitory effect of ICP22
on IE gene expression or that ICP22 can partially reverseprotein kinase which was previously observed to phos-
phorylate ICP22 (Purves and Roizman, 1992), the effect the inhibitory effect of UL13.
on pIGA72 expression of the simultaneous presence in
COS cells of the plasmids pEX22 and pEXUL13 was ana- DISCUSSION
lyzed; the results are shown in Fig. 5 (left). The UL13
gene product strongly inhibited CAT expression under Our data indicate that, under the experimental condi-
tions used in this work, ICP22 inhibits CAT expressionthe control of a4 promoter, the effect being dose-depen-
dent (columns 1 to 4). One microgram of UL13 vector under the control of HSV-1 IE promoters, including the
a22 (IE4) promoter itself. The effect seems to be HSV1(pEXUL13) inhibited pIGA72 activity by 76% (column 2),
while the same amount of pEX22 gave 64% inhibition promoter-specific, since ICP22 did not inhibit the SV40
and HCMV promoters, and it occurred when the protein(column 6). The combination of 1 mg each of pEXUL13
and control plasmid pEX (column 10) resulted in 81% was expressed under the control of two different heterol-
ogous promoters (SV40 and HCMV) in two different cellinhibition, while that of 1 mg each of pEXUL13 and pEX22
(column 7) resulted in only 38% inhibition. When pEXUL13 lines (COS and Rat-1).
Expression of, and inhibition by, ICP22 was greatestwas present in excess over pEX22, the inhibition results
were similar to those seen with pEXUL13 alone (columns when it was expressed in COS cells under the control
of the SV40 promoter (pEX22), with 1 mg of pEX22 or 28 and 3, 9 and 4). A similar degree of reversal of ICP22
inhibition occurred when the amount of SV40 promoter mg of pCMV22 being sufficient to produce 50% inhibition
of pIGA72 in these cells (Fig. 2B). In Rat-1 cells, moredriving ICP22 and UL13 was normalized for all samples
using a plasmid containing only the SV40 promoter (pEX) pEX22 and pCMV22 were required to produce the same
degree of inhibition (Fig. 3B). The data in the two cell(data not shown). The mean inhibition produced by 5 mg
of pIGA72 in three different experiments was 74 { 2.6% types were qualitatively similar, despite the fact that COS
and Rat-1 cells differ in their ability to support the growthfor 2 mg of pEX22, 77.7 { 2.4% for 1 mg of pEXUL13, and
10.3 { 2.3% for 2 mg of pEX22 in the presence of 1 mg of the ICP22-deleted mutant (Sears et al., 1985).
It is interesting to note that ICP22 and other alphaher-of pEXUL13.
To confirm these results, pCMV22 and pEXUL13 were pesvirus ICP22-like proteins (PRV, RSp40; EHV1, IR4
ORF; BHV1, BICP22; and VZV, gene 63) show some struc-tested in COS cells for their ability to inhibit CAT expres-
sion under the control of pIGA72; the results are shown tural homology in their central part, a possible DNA-bind-
ing region. The kinetics of the expression of ICP22 homo-in Fig. 5 (right). Increased inhibition of CAT expression
was seen with increasing concentrations of pCMV22 logs differ during the course of infection. In the case of
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pseudorabies virus (PRV), the ICP22 homolog is an early undergoes partial phosphorylation of its carboxy-terminal
domain (CTD), producing a form which is probably moregene (Zhang and Leader, 1990); in equine herpes virus
1 (EHV1), its homolog is expressed, under various pro- adapted to viral than to cellular transcription (Rice et al.,
1994). More recently, this modification has been shownmoters, depending on the phase of the permissive cycle,
first as an early gene, then as a g1 gene (Holden et al., to require ICP22 synthesis, but it was not possible to
relate this to the cell-type-dependent growth phenotype1992); in transient assays, it enhances the transactivation
of IE, early, and late promoters when expressed in combi- of ICP22-deleted mutants (Rice et al., 1995). The authors
suggest that the UL13 protein may be an ICP22-depen-nation with others transactivators (Holden et al., 1995);
and in bovine herpes virus 1 (BHV1), BICP22 is expressed dent CTD kinase. Our data, and those of others, regard-
ing the similarity of the phenotypes of UL13- and ICP22-with IE or L kinetics, under the control of a single pro-
moter (Schwyzer et al., 1994). According to cycloheximide deleted mutants (Purves et al., 1993) suggest that UL13
can modify the phosphorylation of ICP22, and thus itsexperiments, only BICP22 and gene 63, the ICP22 coun-
terpart in VZV, are regulated in the same way as ICP22 function, in a similar manner to CK2, which acts directly
or indirectly on the regulation of many cellular or viralof HSV1 (Schwyzer et al., 1994; Debrus et al., 1995). In
transfection experiments, the gene 63 product inhibits IE genes (Meisner and Czech, 1991; Allende and Allende,
1995).promoters (Jackers et al., 1992). Although more recent
experiments have not confirmed these results (Kost et ORF 47, the UL13 VZV homolog, although unable to
phosphorylate ORF 63, the ICP22 homolog (Heinemanal., 1995), the similar kinetics of VZV and HSV1 ICP22
homologs might be related to similar functions during and Cohen, 1995), can phosphorylate ORF 62, the ICP4
homolog (Ng et al., 1994). Moreover, ORF 63 can bethe IE infection stage.
The product of the UL13 gene, a serine-threonine pro- phosphorylated by protein kinase CK2 (Stevenson et al.,
1996). HSV1 ICP22 has 120 amino acids in its N-terminaltein kinase, is reported to be involved in ICP22 matura-
tion (Purves and Roizman, 1992). We therefore con- region, which are absent in the PRV, EHV1, BHV1, and
VZV homologs (Zhang and Leader, 1990; Schwyzer et al.,structed vectors expressing this protein to determine
whether its presence could modify the inhibitory activity 1994); these make up two acidic blocks, one N-terminal
to residue 12 and the second between residues 36 andof ICP22. The vector was found to be functional, since it
was able to phosphorylate both itself and casein. Surpris- 69, containing a high proportion of serine/threonine resi-
dues (Fig. 6) and at least four S*/T*-X-X-D/E consensusingly, we observed that UL13 itself was able to inhibit
CAT expression under the a4 promoter, suggesting that sequences close to b-turns, potential targets for phos-
phorylation by protein kinase UL13 and/or CK2 (Pinna,the UL13 gene product might act as a gene expression
regulator, probably via phosphorylation of cellular tran- 1990). Moreover, the R/P-R-A-P/S-R sequence, a site of
nucleotidylylation of ICP22, an event which apparentlyscriptional factors. Although either expression vector
(pEX22 or pEXUL13) was able to inhibit CAT expression takes place at the IE stage of infection (Mitchell et al.,
1994), is also located in this part of the molecule betweenunder the control of the a4 promoter, their effects were
not additive. Furthermore, when present at a particular residues 76 and 80.
In addition, as found with EHV1 (Holden et al., 1992),molar ratio, a reproducible significant reduction of CAT
inhibition was seen. Similar results were seen when a new transcript, 3* coterminal with the mRNA encoded
by the a22 gene and directing the synthesis of a newpCMV22 was used instead of pEX22. The ratio of the two
proteins required to produce partial reversal of inhibition protein corresponding to the C-terminal part of ICP22,
has recently been found (Carter and Roizman, 1996). Thesuggests a stoichiometric interaction, as seen with other
protein kinases, such as casein kinase II (CK2) (Meisner authors postulate that ICP22 encodes at least two sets
of functions, the first mapping to the C-terminal half ofand Czech, 1991) and cAMP protein kinase (Jesse Chan
et al., 1982). the molecule and responsible for the wild-type phenotype
absent from cells infected with R325 (Sears et al., 1985)In our Western blot experiments, using specific antise-
rum, several forms of ICP22 were seen, with the band or 22n199 (Rice et al., 1995) mutants and the second
mapping in the N-terminal region, which may be modu-ratios differing between transfected and infected COS
cells and the faster migrating band being dominant in lated by nucleotidylylation by CK2 and phosphorylation
by viral protein kinases (UL13 and US3). The modulationtransfected cells (Fig. 1); this band, corresponding to the
unprocessed molecule, is the only form found in cells of IE expression by phosphorylation of ICP22, like the
phosphorylation of the CTD domain of polymerase II in-infected by a UL13-deleted mutant and in cells infected
by wild-type virus in the presence of cycloheximide volving ICP22, also appears to be cell-type-independent
(since identical results were seen in both COS and Rat1(Purves et al., 1993). Thus, in the transient experiments
performed in the absence of UL13, ICP22 was either cells) and is probably related to the N-terminal part of
ICP22.nonphosphorylated or less phosphorylated and had un-
dergone less maturation than in infected cells. On the basis of these and our own findings, we sug-
gest that, at the IE infection stage, ICP22 is either non-During infection, the large subunit of polymerase II
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FIG. 6. Predicted secondary structure, distribution of acidic and basic residues, and amino acid sequence of ICP22. The amino acid sequences
were analyzed according to Garnier et al. (1978). Three conformational states are shown: a helix (Ò), sheet (– – –), and b turn (), with the
blank regions being coil strands. The middle part of the figure shows basic and acidic residues (above and below the line, respectively). Individual
residues are indicated by the length of the lines (E  D and R  K  H), as previously reported (Zhang and Leader, 1990). The lowest part of the
figure shows the amino acid sequence of ICP22. Specific amino acids involved in helices are underlined and the S*/T*-X-X-E/D sequences (Meisner
and Czech, 1991) are indicated in bold and underlined.
phosphorylated or only slightly phosphorylated and can low levels of phosphorylation. Our data probably demon-
strate a mechanism which might be difficult to observeact as a repressor of IE expression, while, at a later
stage, it is modified, mainly by newly synthesized viral in infected cells, either because phosphorylation might
be cycling on and off (Wilcox et al., 1980) or becauseprotein kinases UL13, resulting in both the loss of inhibi-
tory effect and its involvement in late expression at the other viral factors might hide, or compensate for, the
effect. In addition, the regulatory function of this proteintranscriptional or posttranscriptional level as previously
observed (Purves et al., 1993). This mechanism is not is probably related not only to its posttranslational modifi-
cation but also to its subcellular localization, which itselfyet understood, but ICP22 might, like the ICP22 EHV1
homolog, increase the binding of ICP4 to viral promoters depends, either directly or indirectly, on these modifica-
tions.and be involved in the regulation of viral expression
(D. J. O’Callaghan, personal communication) or increase
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